Johnson & Johnson reports first-quarter sales above expectations
Share:
(Reuters) - Johnson & Johnson reported first-quarter revenue above analysts' estimates on Tuesday, driven partly by demand for its Stelara treatment for psoriasis and Crohn's disease and cancer drugs Darzalex and Imbruvica.J&J, the first major drugmaker to report first-quarter results, reported a slight rise in quarterly sales to $20.02 billion (£15.31 billion), above the average analyst estimate of $19.61 billion, according to IBES data from Refinitiv.The U.S. healthcare conglomerate said net..